APP and Alzheimer disease: In support for such a hypothesis, recent studies showed that Gja1-deficiency or a connexin inhibitor (Boldine) treatment in APP/PS1 mice had beneficial effects [73, 96, 97], underscoring that Cx43 is a critical mediator of AD pathophysiology and an important therapeutic target for LOAD.